Lancet Oncology

Article	Citations
Use of artificial intelligence to enhance detection of nodal metastases	857
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	603
Patients with cancer in Louisiana denied fertility preservation cover	540
Combination immunotherapy in chemotherapy in gastric cancer	516
US FDA proposes stronger laboratory test oversight	466
Correction to Lancet Oncol 2022; 23: 1124–26	418
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	399
IVLBCL mimicking VEXAS syndrome	397
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	376
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	365
The GLOW trial in chronic lymphocytic leukaemia	357
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer	316
Dual therapy in metastatic castration-resistant prostate cancer	312
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	311
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	311
Study bolsters concerns about US FDA accelerated drug approvals	308
Olanzapine for chemotherapy-induced nausea and vomiting control	306
CAR T cells for the long run in aggressive B-cell lymphoma	288
Correction to Lancet Oncol 2021; 22: 1081–92	284
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	279
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC	279
The future of precise cancer chronotherapeutics	265
A new generation of comprehensive precision oncology trials	261
Survivorship after neoadjuvant chemotherapy	252
Italy to pass law on the right to be forgotten for cancer survivors	250

Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply	240
SANO trial: innovations, risks, and unanswered questions	238
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	235
Concern for cancer drugs in USA–EU tariff war	224
Palliative radiotherapy for hepatic cancer pain	224
US Surgeon General calls for cancer warning labels on alcohol	218
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	215
Innovation in gynaecological cancer: highlighting global disparities	211
Determining the optimal use of approved drugs in oncology	209
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	208
Precision medicine for children with cancer	206
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	199
Health insurance system in Japan faces risk of politicisation	196
Navigating the complexity: reflections on the development of perioperative cancer treatments	194
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	193
The silent malignant mesothelioma epidemic: a call to action	193
Medical treatment for active breast cancer brain metastases	191
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	188
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	187
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	184
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	183
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	182
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	181
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial	180
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	179
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	175
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	172
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery	172
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	168
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	168
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	167
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	165
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial	163
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply	160
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX	159
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus	156
New national cancer registry for France	155
Focus where it matters: turning insights into advocacy	154
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	151
A biobank perspective on use of tissue samples donated by trial participants	149
Common Sense Oncology: including everyone	148
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	148
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply	147
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	147
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	146
Essential anticancer medicines for children: defining what matters most for Europe	145
Importance of clinical research for the UK's 10-year cancer plan	140
Radiotherapy with genomic-adjusted radiation dose	139
Radiotherapy with genomic-adjusted radiation dose	139
Mantle cell lymphoma: is it time for risk-adapted treatment?	139

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	138
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	137
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	136
Lung cancer rates highest among British Bangladeshi men	134
Antimicrobial resistance in patients with haematological malignancies: a scoping review	133
WHO reports health service disruptions due to suspensions of aid	132
Decentralised, point-of-care CAR-T for multiple myeloma	130
Balancing clinical benefit and social value: challenges in HTA assessments	130
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	127
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	126
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	123
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study	123
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	123
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	121
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	118
Cancer on the agenda during IAEA Director General's visit to Chile	118
Challenges and prospects for cancer treatment in prison settings	116
Daratumumab maintenance in patients with myeloma	116
Correction to Lancet Oncol 2020; 21: 699–709	115
Correction to Lancet Oncol 2023; 24: e242	115
2022 ASTRO annual meeting	114
Clearing the radiotherapy backlog: innovation to pave the way	114
Radiotherapy and conflict: from disruption to expansion and hope	112
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	112
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	111
Shortages of essential medications for children with cancer in Colombia	111
A growing vulvar mass in a post-menopausal woman	111
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	110
Syrian cancer patients regain treatment access in Türkiye	108
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	108
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	106
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	106
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis	105
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	104
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	104
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	100
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	100
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	98
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	97
India rolls out HPV vaccination	95
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	95
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	94
Endometrial cancer: the individual approach	91
Oral contraceptives and risk of liver cancer	91
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	91
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting	90
Managing immune checkpoint inhibition in transplant recipients	90
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	89
AACR Annual Meeting 2023	87
The thin border between individual and collective ethics: the downside of GDPR	86
ROAR trial: which treatment is effective after progression?	86
Correction to Lancet Oncol 2021; 22: 1497–98	84
Correction to Lancet Oncol 2024; 25: e126–35	83
Shortage of cancer drugs in Mexico	83
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	82
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	82
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	81
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA	80
On a precipice: the UK's broken health-care system	79
Medical debt of people with cancer in the USA	78
Promoting cancer prevention through World Cancer Day in Nigeria	78
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	77
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	77
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	77
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	76
Internationally trained doctors in the USA	75
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	75
Screening for breast cancer brain metastases	75
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	74
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	73
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose	72
Correction to Lancet Oncol 2023; 24: 1181–95	72
Transforming cancer: behind the scenes at the Crick Institute	72
South Africa's new tobacco and e-cigarette control bill	72
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	72
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	72
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label,	71
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	71
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	71
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	70

Mozambique takes on cancer burden challenges	69
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	69
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	69
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	68
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-lab	68
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	68
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	67
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	67
Quality control and childhood cancer medicines	67
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	67
Code of practice needed for samples donated by trial participants – Sponsor's reply	67
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	66
Correction to Lancet Oncol 2016; 17: 484–95	66
US lawmakers call on Biden Administration to lower the price of enzalutamide	66
Correction to Lancet Oncol 2022; 23: 1297–307	66
Correction to Lancet Oncol 2023; 24: e472–518	66
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	66
Correction to Lancet Oncol 2023; 24: 91–106	66
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	65
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study	65
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	65
Sintilimab plus IBI305 for hepatocellular carcinoma	64
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	64
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	64
Stereotactic ablative radiotherapy for primary kidney cancer	63
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	63
New evidence for brain cancer risk after a single paediatric CT scan	62
Essential medicines list in national cancer control plans: a secondary analysis from a global study	61
US legislation might soon allow easier access to cancer medications	61
Problems with catch-up HPV vaccination after resumption of proactive recommendations	61
PSMA-PET research: addressing challenges and prospects – Authors' reply	61
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	61
Challenging cancer through poetry	60
American Lung Association calls for expanded insurance coverage for lung cancer screening	59
Anticipating the future of cancer care in Trump's America	58
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	57
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	57
Qatar national cancer care and research: pioneering strategies for global health excellence	57
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	57
Rwanda provides free treatment to all cancer patients	57
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	56
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease	56
Abemaciclib for malignant pleural mesothelioma – Authors' reply	56
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer	56
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	55
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	54
Sharp increase in patients waiting months for urgent cancer treatment	54
Management of locally advanced gastric cancer	54
Sharing a personal story behind brain cancer	54
Immunotherapy: balancing the risks and benefits	53
US Clean Air in the firing line	52
Poor cancer care in Zimbabwe	52
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	52
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	52
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-	52
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	51
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean	51
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	51
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	50
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label	50
HPV vaccine roll-out in Nigeria and Bangladesh	50
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	50
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial	50
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	50
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	49
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	49
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, op	49
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resul	48
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	48
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	48
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	47
The changing global landscape of national cancer control plans	47
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	47
Thank you to The Lancet Oncology's reviewers in 2022	46
Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors	46
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer	46
Thoracic CT follow-up after non-small-cell lung cancer resection	46
Indonesia and the Philippines take steps to control cancer	46
Improved cancer coverage for firefighters in Western Australia	46
US cancer research might never recover from proposed Trump funding cuts	46
Cancer in sub-Saharan Africa: key research and action gaps	46
Transforming Canada's role in global cancer control	46
Place of death of people with cancer in 12 Latin American countries: a total population study using national death registers	45
Losing my brother, finding myself	44
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	43
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer – Authors' reply	43
Treatment of Richter transformation—immunotherapy to the rescue?	43
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	43
Correction to Lancet Oncol 2024; 25: 744–59	42
Correction to Lancet Oncol 2022; 23: 393–405	42
Correction to Lancet Oncol 2022; 23: 416–27	42
Correction to Lancet Oncol 2024; 25: 317–25	42
Correction to Lancet Oncol 2021; 22: 1250–64	41
Utilising cancer registry data to monitor cancer burden	41
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm	41